Conflicts seen on guidelines panel

Share this article:

The AHA/ACC panel that wrote the potentially practice-changing cholesterol guidelines issued last month included six members with ties to drugmakers that sell or are developing lipid medications, Pharmalot reported. Each disclosed they worked as a consultant and received funding for personal research.

Among the 10 expert reviewers, half listed consulting relationships with such companies cited as Merck, Amgen, AstraZeneca, Pfizer, Amarin, Roche and Abbott Laboratories, whose cholesterol pills are sold by AbbVie. An AHA spokeswoman responded that none of the ACC/AHA expert reviewers had “relevant” relationships with industry.

Share this article:

Email Newsletters

More in Features

Antidote: On Cystic Fibrosis treatments

Antidote: On Cystic Fibrosis treatments

Recent treatments in CF, including the inhaled antibiotic Tobramycin, have increased lifespan well into adulthood.

The $3 generic and the $1,000 pill: pharma outsiders just don't get it

The $3 generic and the $1,000 pill: pharma ...

What do you call the people who treat medical breakthroughs as if they were bank heists? Malicious? Uninformed? Not with it?

Leadership Exchange Uncut : The Agency-Client Relationship

Leadership Exchange Uncut : The Agency-Client Relationship

Click the above link to access MM&M's first Leadership Exchange Uncut e-book, "The Agency-Client Relationship"